Randomized crossover study of latanoprost and travoprost in eyes with open-Angle glaucoma

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 1, 2012, Pages 123-129

  Sawada, Akira ^a   Yamamoto, Tetsuya ^a   Takatsuka, Naoyoshi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Central corneal thickness; Intraocular pressure; Latanoprost; Travoprost

Indexed keywords

LATANOPROST; PROSTAGLANDIN DERIVATIVE; TRAVOPROST;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA THICKNESS; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; EYELID DISEASE; FEMALE; FOLLOW UP; HUMAN; HYPERTRICHOSIS; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISUAL ACUITY;

EID: 85027943941     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1762-1     Document Type: Article

References (47)

1. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, Inoue Y, Kitazawa Y, Tajimi Study Group, Japan Glaucoma Society (2004) The prevalence of primary open-angle glaucoma in Japanese. The Tajimi Study. Ophthalmology 111:1641-1648 (Pubitemid 39179676)
2. Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487-497
3. Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI (2008) Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 17:217-222 (Pubitemid 351543547)
4. Chew PT, RojanaPongpun P, Euswas A, Lu D, Chua J, Hui S, Rait J, Goldberg I, Li B, Travatan CACG Study Group (2006) Intraocular pressure-lowering effect and safety of travoprost 0.04% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian J Ophthalmol 8:13-19
5. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132:472-484 (Pubitemid 32904567)
6. Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP (2008) The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 22:179-183 (Pubitemid 351266454)
7. Bean GW, Camras CB (2008) Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 53(suppl 1):S69-S84
8. Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R (2007) A 6-week, multicenter, randomized, doublemasked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther 29:1915-1923 (Pubitemid 350212801)
9. Hepsen IF, Ozkaya E (2007) 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye 21:453-458. (Pubitemid 46564134)
10. García-Feijoo J, Martínez-de-la-Casa JM, Castillo A, Méndez C, Fernández-Vidal A, García-Sánchez J (2006) Circadian IOPlowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin 22:1689-1697 (Pubitemid 44449225)
11. Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J (2004) Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost. Clin Ther 26:84-91
12. Yan DB, Battista RA, Haidich AB, Konstas AG (2008) Comparison of morning versus evening dosing and 24- h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma. Curr Med Res Opin 24:3023-3027
13. Yildirim N, Sahin A, Gultekin S (2008) The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 17:36-39 (Pubitemid 351321474)
14. Viestenz A, Martus P, Schlötzer-Schrehardt U, Langenbucher A, Mardin CY (2004) Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness - a cross-sectional study on 403 eyes. Klin Monatsbl Augenheilkd 221:753-756 (Pubitemid 39390855)
15. Lass JH, Eriksson GL, Osterling L, Simpson CV, Latanoprost Corneal Effect Study Group (2001) Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology 108:264-271 (Pubitemid 32115954)
16. Brandt JD,GordonMO, Beiser JA, Lin SC,AlexanderMY,KassMA (2008) Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology 115:1550-1556
17. Harasymowycz PJ, Papamatheakis DG, Ennis M, Brady M, Gordon KD (2007) Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea 26:34-41 (Pubitemid 46041561)
18. Stefan C, Dumitrica DM, Tebeanu E, Nae I, Sapundgieva A, Dragomir L (2007) Prostaglandin analogues and central corneal thickness. Oftalmologia 51:95-99
19. Sen E, Nalcacioglu P, Yazici A, Aksakal FN, Altinok A, Tuna T, Koklu G (2008) Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 17:398-402
20. Hatanaka M, Vessani RM, Elias IR, Morita C, Susanna R Jr (2009) The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 25:51-53
21. Johnson TV, Toris CB, Fan S, Camras CB (2008) Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications. J Glaucoma 17:89-99 (Pubitemid 351412396)
22. Johnson M, Kass MA, Moses RA, Crodzki WJ (1978) Increased corneal thickness simulating elevated intraocular pressure. Arch Ophthalmol 96:664-665 (Pubitemid 8301694)
23. Whitacre MM, Stein R (1993) Sources of error with use of Goldmann-type tonometers. Surv Ophthalmol 38:1-30 (Pubitemid 23234285)
24. Whitracre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592-596 (Pubitemid 23137642)
25. Brandt JD (2004) Corneal thickness in glaucoma screening, diagnosis, and management. Curr Opin Ophthalmol 15:85-88
26. Doughty MJ, Zaman ML (2000) Human corneal thickness and its impact on intraocular pressure measures: a review and metaanalysis approach. Surv Ophthalmol 44:367-408 (Pubitemid 30151145)
27. Suh MH, Park KH, Kim DM (2009) Effect of travoprost on intraocular pressure during 12 months of treatment for normaltension glaucoma. Jpn J Ophthalmol 53:18-23
28. Nomura Y, Nakamura S, Moriwaki M, Takahashi Y, Shiraki K (2010) Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol 4:643-647
29. Ang GS, Kersey JP, Shepstone L, Broadway DC (2008) The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomized controlled trial. Br J Ophthalmol 92:1129-1133
30. Ehlers N, Bramsen T, Sperling S (1975) Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh) 53:34-43
31. Whitacre MM, Stein RA, Hassanein K (1993) The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 115:592-596 (Pubitemid 23137642)
32. Brandt JD, Beiser JA, Kass MA, Gordon MO (2001) Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 108:1779-1788 (Pubitemid 32905932)
33. Iester M, Mete M, Figus M, Frezzotti P (2009) Incorporating corneal pachymetry into the management of glaucoma. J Cataract Refract Surg 35:1623-1628
34. Sit AJ, Weinreb RN, Crowston JG, Kripke DF, Liu JH (2006) Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 141:1131-1133 (Pubitemid 43831052)
35. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX (2003) Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19:501-515 (Pubitemid 38030237)
36. Miglior S, Albe E, Guareschi M, Mandelli G, Gomarasca S, Orzalesi N (2004) Intraobserver and interobserver reproducibility in the evaluation of ultrasonic pachymetry measurements of central corneal thickness. Br J Ophthalmol 88:174-177 (Pubitemid 38142079)
37. Wickham L, Edmunds B, Murdoch IE (2005) Central corneal thickness: will one measurement suffice? Ophthalmology 112:225-228 (Pubitemid 40202556)
38. Ornek K, Gullu R, Ogurel T, Ergin A (2008) Short-term effect of topical brinzolamide on human central corneal thickness. Eur J Ophthalmol 18:338-340
39. Smith VA, Hoh HB, Littleton M, Easty DL (1995) Overexpression of a gelatinase A activity in keratoconus. Eye 9:429-433
40. Weinreb RN, Lindsey JD (2002) Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43:716-722 (Pubitemid 34187638)
41. Mietz H, Schlötzer-Schrehardt U, Strassfeld C, Krieglstein GK (2001) Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. Invest Ophthalmol Vis Sci 42:679-687 (Pubitemid 32206908)
42. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN (1999) Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117:794-801 (Pubitemid 29265042)
43. Fellman RL, Sullivan EK, Ratliff M, Silver LH, Whitson JT, Turner FD, Weiner AL, Davis AA, Group TS (2002) Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 109:998-1008 (Pubitemid 34465238)
44. Camras CB (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138-147 (Pubitemid 26046170)
45. Peplinski LS, Albiani Smith K (2004) Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci 81:574-577 (Pubitemid 39095648)
46. Yang HK, Park KH, Kim TW, Kim DM (2009) Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol 53:176-179
47. Yam JC, Yuen NS, Chan CW (2009) Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther 25:471-472.